Peter Lischka

Senior Director Virology / Head Translational Science at AiCuris Anti-infective Cures AG

Speaker

Peter Lischka is a seasoned virologist with an extensive background in preclinical, and clinical virology, applied to the development of antiviral agents against significant viral pathogens.

With more than 20 years of experience in virology, he has a broad expertise in antiviral drug discovery and development. He is currently serving as the Senior Director Virology and Head of Translational Science at AiCuris Anti-infective Cures AG.

During his career, Peter has worked on several virus indications, with a strong focus on viral infections in immunocompromised transplant patients such as cytomegalovirus (CMV), adenovirus (AdV), herpes simplex virus (HSV), and BK polyomavirus (BKV). His work spans various antiviral principles, including small molecule drugs, biological immunomodulators, and oligonucleotide antiviral therapeutics.

Peter was instrumental in research and development of Letermovir (Prevymis®) and was a key contributor to the approval of this anti-CMV drug, which is now considered the gold standard for prophylactic therapy of CMV infections in bone marrow transplant patients and kidney transplant recipients